An ascending single dose study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of SBI-087 administered to subjects with rheumatoid arthritis.

Trial Profile

An ascending single dose study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of SBI-087 administered to subjects with rheumatoid arthritis.

Completed
Phase of Trial: Phase I

Latest Information Update: 12 Apr 2016

At a glance

  • Drugs SBI 087 (Primary) ; SBI 087 (Primary)
  • Indications Rheumatoid arthritis
  • Focus Adverse reactions
  • Most Recent Events

    • 12 Apr 2016 Results of pooled analysis of two trials (NCT00641225 and NCT00714116) published in the Clinical Therapeutics
    • 13 Mar 2012 Actual end date (March 2011) added as reported by ClinicalTrials.gov.
    • 13 Mar 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top